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Background
Microbicide strategies against HIV must interrupt the crit-
ical cell-virus interactions that lead to infection, including
envelope interactions with CD4, chemokine receptors,
and C-type lectin receptors. We have recently identified a
novel, highly specific approach to inhibit HIV infection
using the Designed Ankyrin Repeat Protein (DARPin)
technology [1]. DARPins are based on the principle of nat-
urally occurring ankyrin repeat proteins, and binders can
be selected against targets with high affinity and specificity
from randomized libraries. These features, combined with
a remarkable physical stability and relatively low cost pro-
duction in procaryotes render DARPins extremely promis-
ing candidates for the selection of HIV inhibitors.
Methods
DARPin molecules specific for a HIV gp120 core stabilized
in the CD4 bound state [2] were selected via ribosome dis-
play.
Results
Off-rate selection allowed the selection of DARPin bind-
ers with highly specific binding and antiviral activity
against autologous as well as heterologous viral isolates.
Conclusion
Our initial proof of concept studies documented the selec-
tion of CD4-specific DARPins that are highly specific and
efficiently prevent in vitro infection with a wide range of
HIV as well as SIV isolates at nanomolar levels, without
interfering with basic cellular functions [3]. We now
report on the identification of gp120 specific DARPins
with inhibitory activity.
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